CANAGLIFLOZIN IMPROVES ERYTHROPOIESIS IN DIABETES PATIENTS WITH ANAEMIA OF CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Maruyama, Takashi [1 ]
Takashima, Hiroyuki [1 ]
Abe, Masanori [1 ]
机构：
[1] Nihon Univ, Sch Med, Tokyo, Japan
来源：
NEPHROLOGY | 2020年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
467
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [31] Differentiating factors between erythropoiesis-stimulating agents -: A guide to selection for anaemia of chronic kidney disease
    Deicher, R
    Hörl, WH
    DRUGS, 2004, 64 (05) : 499 - 509
  • [32] Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
    Chung, Edmund Y. M.
    Palmer, Suetonia C.
    Saglimbene, Valeria M.
    Craig, Jonathan C.
    Tonelli, Marcello
    Strippoli, Giovanni F. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (02):
  • [33] The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study
    New, J. P.
    Aung, T.
    Baker, P. G.
    Yongsheng, G.
    Pylypczuk, R.
    Houghton, J.
    Rudenski, A.
    New, R. P.
    Hegarty, J.
    Gibson, J. M.
    O'Donoghue, D. J.
    Buchan, I. E.
    DIABETIC MEDICINE, 2008, 25 (05) : 564 - 569
  • [34] Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
    Walter H. Hörl
    Drugs, 2013, 73 : 117 - 130
  • [35] Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
    Vicente Escudero-Vilaplana
    Concepción Martínez-Nieto
    Juan Manuel López-Gómez
    Almudena Vega-Martínez
    José María Bellón-Cano
    María Sanjurjo-Sáez
    International Journal of Clinical Pharmacy, 2013, 35 : 463 - 468
  • [36] Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
    Escudero-Vilaplana, Vicente
    Martinez-Nieto, Concepcion
    Manuel Lopez-Gomez, Juan
    Vega-Martinez, Almudena
    Maria Bellon-Cano, Jose
    Sanjurjo-Saez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (03) : 463 - 468
  • [37] Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4
    Sridhar, Vikas S.
    Davies, Michael J.
    Banks, Phillip
    Girard, Manon
    Carroll, Amy K.
    Cherney, David Z. I.
    DIABETES OBESITY & METABOLISM, 2024,
  • [38] Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease
    Robert Deicher
    Walter H. Hörl
    Drugs, 2004, 64 : 499 - 509
  • [39] Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
    Hoerl, Walter H.
    DRUGS, 2013, 73 (02) : 117 - 130
  • [40] Association of circulating autoantibodies to erythropoietin receptor with anaemia in patients with type 2 diabetes and chronic kidney disease
    Oshima, Megumi
    Toyama, Tadashi
    Ito, Kiyoaki
    Kitajima, Shinji
    Mizushima, Ichiro
    Hara, Akinori
    Sakai, Norihiko
    Shimizu, Miho
    Wada, Takashi
    Iwata, Yasunori
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2740 - I2740
12345